Product guide · Restricted substance
GynSyn Labs LGD-4033 30 ml (1ml 20mg)
Research compound from GynSyn Labs, 30 ml of liquid. This guide sets out what the manufacturer states about the composition of GynSyn Labs LGD-4033 30 ml (1ml 20mg), what independent research says about its main ingredient, and the safety and regulatory points that apply. It contains substances that are not authorised as food or medicine in the EU. This guide is educational: it does not recommend use and gives no directions for use.
Back to the product- Named ingredients
- 1
- Amounts stated
- All
- Status
- Restricted substance
- Evidence summaries
- 1
Overview
Manufacturer informationGynSyn Labs LGD-4033 30 ml (1ml 20mg) contains LGD-4033 (Ligandrol): 20 mg. Each pack holds 30 ml (liquid).
Ingredients & composition
Manufacturer information| Ingredient | Amount |
|---|---|
| LGD-4033 (Ligandrol) | 20 mg |
Scientific background
Independent researchLGD-4033 (ligandrol)
LGD-4033 (ligandrol) is a non-steroidal selective androgen receptor modulator developed as an investigational drug for muscle wasting1.
Research evidence
Independent researchLGD-4033 (ligandrol)
In a 21-day randomised, placebo-controlled trial in 76 healthy young men, LGD-4033 increased lean body mass. It also caused dose-dependent suppression of total testosterone, sex hormone-binding globulin, HDL ("good") cholesterol and triglycerides1.
A systematic review of randomised SARM trials reports positive effects on body composition and physical performance with moderate rates of mild to moderate adverse effects2.
Evidence limitations
Independent researchNo published study has tested this specific product; the research summarised here concerns the ingredient itself.
LGD-4033 (ligandrol)
The human data come from short trials at low doses under medical supervision. There are no long-term safety or outcome data1. Analyses of products sold online as SARMs found that many did not contain the substance or amount stated on the label, and some contained other unapproved drugs3.
Safety & potential risks
Independent researchLGD-4033 (ligandrol)
Cholestatic liver injury, confirmed by biopsy, has been reported in a person using ligandrol4. A systematic review of SARM use by athletes reports liver toxicity, heart toxicity, tendon damage, suppression of natural testosterone and other androgenic effects5. A national case series linked SARMs and other bodybuilding products to drug-induced liver injury6.
Regulatory status
Contains a selective androgen receptor modulator (SARM). SARMs are investigational substances that are not authorised as medicinal products or as food (including food supplements) in the EU and are on the World Anti-Doping Agency (WADA) Prohibited List. No dosing information for human use is provided.
Scientific references
- Basaria S, Collins L, Dillon EL, et al. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci. 2013;68:87-95. PubMed 22459616
- Wen J, Syed B, Leapart J, et al. Selective androgen receptor modulators (SARMs) effects on physical performance: a systematic review of randomized control trials. Clin Endocrinol (Oxf). 2025;102:3-27. PubMed 39285652
- Van Wagoner RM, Eichner A, Bhasin S, et al. Chemical composition and labeling of substances marketed as selective androgen receptor modulators and sold via the internet. JAMA. 2017;318:2004-2010. PubMed 29183075
- Barbara M, Dhingra S, Mindikoglu AL. Ligandrol (LGD-4033)-induced liver injury. ACG Case Rep J. 2020;7:e00370. PubMed 32637435
- Vasireddi N, Hahamyan HA, Gould HP, et al. Athlete selective androgen receptor modulators abuse: a systematic review. Am J Sports Med. 2025;53:999-1009. PubMed 39755947
- Nash E, Nicoll A, Batt N, et al. Drug-induced liver injury from selective androgen receptor modulators, anabolic-androgenic steroids and bodybuilding supplements in Australia. Aliment Pharmacol Ther. 2024;59:953-961. PubMed 38372012
- Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal of the European Union. Source
- Regulation (EU) 2015/2283 on novel foods. Official Journal of the European Union. Source
- Thevis M, Schänzer W. Detection of SARMs in doping control analysis. Mol Cell Endocrinol. 2018;464:34-45. PubMed 28137616
- World Anti-Doping Agency. The Prohibited List (current edition). Source
Sources checked against PubMed, Crossref or the official publisher on 2026-11-04. Manufacturer information is taken from the product's own data and has not been independently tested.
The product
GynSyn Labs LGD-4033 30 ml (1ml 20mg)
€52,00 · Sold out